Prospective Non Interventional Phase IV Multi-centre Canadian Study on the Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion Under 63 Days Gestation

National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of pregnancy at or before 63 days gestational age through a multi-center prospective non interventional study design.

开始日期2022-02-22

申办/合作机构

Linepharma International Ltd.

NCT05049980 / CompletedN/AIIT

Evaluation of the Efficacy, Tolerance of the Treatment, and Patient Satisfaction During the Management of an Arrested Pregnancy in the First Trimester According to the New Toulouse University Hospital Protocol

The clinical practice recommendations highlight the fact that the patient's choice concerning the management of her aborted pregnancy in the first trimester should be privileged, after clear and appropriate information on the available treatments, in order to improve his experience and reduce the negative psychological symptoms that can generate an alteration in the quality of life, in the aftermath of the loss of pregnancy.
The present study will describe the efficacy, satisfaction and tolerance of patients benefiting from medical treatment with Mifégyne® and MisoOne® versus those benefiting from surgical treatment by endo-uterine aspiration for the management of a pregnancy stopped during the first trimester at the Toulouse University Hospital

开始日期2021-11-01

申办/合作机构-

NCT03043014 / CompletedN/AIIT

Cervical Preparation of Abortions Under Paracervical Block in the First Trimester: A Randomized Clinical Trial

Surgical abortion is one of the most frequently surgery of women in the world. 43 millions are annually performed in the world.
90% of the abortions are performed during the first trimester of pregnancy before 13 weeks. Legal surgical abortion during the first trimester of pregnancy is a low risk intervention with a mortality rate lower than 1/100 000 abortions, with a risk of complications from 0.3 % to 3.4 %.

开始日期2017-06-01

申办/合作机构

Assistance Publique Hôpitaux de Marseille

100 项与米非司酮/米索前列醇相关的临床结果

登录后查看更多信息

100 项与米非司酮/米索前列醇相关的转化医学

登录后查看更多信息

100 项与米非司酮/米索前列醇相关的专利（医药）

登录后查看更多信息

447

项与米非司酮/米索前列醇相关的文献（医药）

2024-11-01·Research in Veterinary Science

Effect of the addition of exogenous progesterone and the progesterone receptor inhibitor (RU 486) on boar cryopreservation semen extenders

Article

作者: de Mercado, Eduardo ; Martín-San Juan, Adrián ; Gala, Nerea ; Nieto-Cristóbal, Helena ; Álvarez-Rodríguez, Manuel

Cryopreservation of porcine spermatozoa is detrimental due to their high sensitivity to cold shock, leading to changes akin to capacitation, known as cryocapacitation. These changes, including the acrosomal reaction, hypermotility induction, and protein phosphorylation, might be influenced by the presence of progesterone in seminal plasma and egg yolk, used in most freezing extenders. We tested the effect of various progesterone concentrations added to the freezing extenders (1, 10, and 100 μg/mL). At 100 μg/mL, progesterone decreased the proportion of straightness and tended to reduce viability and the proportion of progressive motility (p < 0.1). At 10 μg/mL, it increased reacted acrosomes in dead sperm (p < 0.05), protein phosphorylation rate (p < 0.05), and tended (p < 0.1) to enhance linear movement compared to the control. To counteract the capacitating effect of progesterone, we examined the effect of antiprogesterone mifepristone (RU 486) at concentrations of 5, 10, 20, 50, 100, and 200 μM, and co-incubated 10 μM of RU 486 with 10 μg/mL of progesterone. RU 486 maintained capacitation levels and motility parameters similar to the control, although high concentrations (100 μM) tended (p = 0.152) to increase protein phosphorylation. Co-incubation reduced the acrosome reaction in dead sperm, and RU 486 appeared to prevent hypermotility stabilizing motility and viability parameters compared to samples with progesterone alone. Protein phosphorylation increased and RU 486 could not restore capacitation to control levels due to its competitive antagonism for progesterone receptors, having less affinity than progesterone, which displaces RU 486 at high concentrations, allowing normal sperm capacitation.

2024-09-01·Free Radical Biology and Medicine

Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression

Article

作者: Liu, Baiping ; Shi, Yanyun ; Chen, Jieping ; Huang, Qilin ; Shang, Yingying ; Fu, Xuemei ; Li, Hui ; Xu, Nahua ; Yao, Qi ; Ma, Yanni

Ferroptosis is a form of iron-dependent cell death that has attracted significant attention for its potential role in numerous diseases. Targeted inhibition of ferroptosis could be of potential use in treating diseases: such as drug induced liver injury (DILI). Ferroptosis can be antagonized by the xCT/GSH/GPX4, FSP1/CoQ₁₀, DHODH/CoQ₁₀, GCH1/BH₄, and NRF2 pathways. Identifying novel anti-ferroptosis pathways will further promote our understanding of the biological nature of ferroptosis and help discover new drugs targeting ferroptosis related human diseases. In this study, we identified the clinically used drug mifepristone (RU486) as a novel ferroptosis inhibitor. Mechanistically, RU486 inhibits ferroptosis by inducing GSH synthesis pathway, which supplies GSH for glutathione-S-transferase (GST) mediated 4-HNE detoxification. Furthermore, RU486 induced RLIP76 and MRP1 export 4-HNE conjugate contributes to its anti-ferroptosis activity. Interestingly, RU486 induced GSH/GSTs/RLIP76&MRP1 anti-ferroptosis pathway acts independent of classic anti-ferroptosis systems: including xCT/GSH/GPX4, FSP1, DHODH, GCH1, SCD1 and FTH1. Moreover, NRF2 was identified to be important for RU486's anti-ferroptosis activity by inducing downstream gene expression. Importantly, in mouse model, RU486 showed strong protection effect on acetaminophen (APAP)-induced acute liver injury, evidenced by decreased ALT, AST level and histological recovery after APAP treatment. Interestingly, RU486 also decreased oxidative markers, including 4-HNE and MDA, and induced NRF2 activation as well as GSTs, MRP1 expression. Together, these data suggest NRF2/GSH/GST/RLIP76&MRP1 mediated detoxification pathway as an important independent anti-ferroptosis pathway act both in vitro and in vivo.

2024-08-01·Tissue and Cell

Cytoarchitectural differences in reproductive organs of some polycystic ovary-like induced animal models

Article

作者: Adetayo Lawal, Ismail ; Yakub, Azeezat Dagbo ; Ajao, Moyosore Salihu ; Ojulari, Lekan Sheriff ; Kadir, Eniola Risikat ; Hussein, Abdulmalik Omogbolahan ; Jaji-Sulaimon, Rukayat

Polycystic ovary syndrome (PCOS) is the most common gynaecological, endocrine disorder that occurs during reproductive age and is a significant cause of anovulatory infertility. Letrozole is an aromatase inhibitor which negates the action of the aromatase enzyme, which results in the buildup of male hormones (testosterone) in the females, causing hyperandrogenism, which is a hallmark of Polycystic Ovarian Syndrome. Mifepristone (RU486) is a progestin antagonist that acts to arrest the actions of the progesterone hormone, resulting in follicular atresia and anovulation. DHEA is an androgen which was also administered in a bid to cause hyperandrogenism in the rats.This study aimed to evaluate the effects of these hormones on the cytoarchitecture of the ovaries and uterus to assess their various PCOS-like histological features.Animals were grouped mainly into three: Letrozole, Mifepristone and DHEA groups, which were further divided into two subgroups each, administered low and high doses of letrozole orally, Mifepristone and Dehydroepiandosterone (DHEA) subcutaneously. Each of the subgroups also had a comparison control group. Following the completion of administration, the Wistar rats were euthanized, and their ovaries and uterus were collected for histological analysis.Increased proliferation of ovarian follicles was noted in the treated groups compared to control, as well as thickening of the endometrial layer.

项与米非司酮/米索前列醇相关的新闻（医药）

2024-02-02

·GlobeNewswire-Health Care

Women’s Health Advocates Call on Province of New Brunswick and Premier Higgs to act urgently following the closure announcement of Clinic 554

OTTAWA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Following the announcement of the closure of Clinic 554 in Fredericton, the Society of Obstetricians and Gynaecologists of Canada (SOGC) calls on the Province of New Brunswick and Premier Higgs to take immediate measures to ensure that all women in New Brunswick have equitable access to surgical abortion. The closure of Fredericton-based Clinic 554 means that women will now only be able to access these services in two cities in the province. Only three hospitals in New Brunswick offer this service. A 2023 research study from the University of New Brunswick found that there are many barriers to accessing services, including general information gaps, payment models, and regional disparities. These long-standing concerns have been exacerbated by this recent announcement. “The health and safety of Canadian women, which includes equitable access to reproductive health care, should be a priority of all levels of government; it should not depend on a woman’s postal code. While Mifegymiso offers another choice, it may not be a suitable option for all individuals due to medical, geographic, or personal concerns. The closure of Clinic 554 limits women’s choice and access to an important medical service in that region of our country. We urge the provincial government and the Premier to reflect on the long-lasting consequences of inequitable access to care and reproductive choices and to act to ensure that we continue to move forward with the health care rights of women in Canada, not backward.”- Dr. Amanda Black, President, Society of Obstetricians and Gynaecologists of Canada Media Inquiries:Kelsey MacDonald Director of Communications and Public Affairs Society of Obstetricians and Gynaecologists of Canada 613-240-2528kmacdonald@sogc.com The Society of Obstetricians and Gynaecologists of Canada is the National Voice on Women’s Health

并购

100 项与米非司酮/米索前列醇相关的药物交易

登录后查看更多信息